Item 1.01. Entry Into a Material Definitive Agreement.

On May 14, 2021, Luckwel Pharmaceuticals Inc. (the "Company") entered a Subscription Agreement with Bounty Company Limited, a company incorporated in the British Virgin Islands (the "Investor"), pursuant to which the Company, in a private placement, agreed to issue and sell to the Investor an aggregate of 187,500 restricted shares of the Company's common stock, par value $0.01 per share (the "Common Stock") at a price per share of $0.40 for gross proceeds of approximately $75,000 (the "Private Placement"). The Private Placement is expected to close on or around May 29, 2021.

The representations, warranties and covenants contained in the Subscription Agreement were made solely for the benefit of the parties to the Subscription Agreement and may be subject to limitations agreed upon by the contracting parties. Accordingly, the Subscription Agreement is incorporated herein by reference only to provide investors with information regarding the terms of the Subscription Agreement and not to provide investors with any other factual information regarding the Company or its business, and should be read in conjunction with the disclosures in the Company's periodic reports and other filings with the SEC.

The foregoing description of the Subscription Agreement is qualified in its entirety by reference to the form of Subscription Agreement, a copy of which are attached hereto as Exhibit 10.1 and incorporated in this Item 1.01 by reference.

Item 3.02 Unregistered Sales of Equity Securities

The information set forth in Item 1.01 hereof is hereby incorporated by reference into this Item 3.02. The issuance of our common stock pursuant to the Subscription Agreement will be exempt from registration pursuant to the provisions of Section 4(a)(2) of the Securities Act of 1933 (the "Securities Act"), as amended and Regulation S under the Securities Act for purposes of the Private Placement of the shares of common stock as such shares have not been offered or sold in the United States or to, or for the account or benefit of, U.S. persons (as defined in Regulation S under the Securities Act) or persons in the United States.

Item 9.01. Financial Statements and Exhibits.





(d) Exhibits



Exhibit
  No.                 Description

10.1        Form of Subscription Agreement.

© Edgar Online, source Glimpses